Next-generation sequencing for lung cancer

Future Oncology

Volumn 9, Issue 9, 2013, Pages 1323-1336

  Wu, Kehua ^a   Huang, R Stephanie ^a   House, Larry ^a   Cho, William Chi ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

lung cancer; next generation sequencing; whole exome sequencing; whole genome sequencing; whole transcriptome sequencing

Indexed keywords

RIBOSOME RNA; RNA POLYMERASE II;

ANCHORAGE INDEPENDENT GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CELL TRANSFORMATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME TRANSLOCATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC CODE; HUMAN; HUMAN GENOME PROJECT; LOSS OF FUNCTION MUTATION; LUNG CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PERICENTRIC CHROMOSOME INVERSION; PERSONALIZED MEDICINE; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA HYBRIDIZATION; RNA SEQUENCE; SOMATIC MUTATION;

GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883309482     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.102     Document Type: Review

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics, 2011. CA Cancer J. Clin. 61(2), 69-90 (2011
2. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: An evolving story. Annu. Rev. Med. 59, 429-442 (2008
3. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11(10), 685-696 (2010
4. Diamandis M, White NM, Yousef GM. Personalized medicine: Marking a new epoch in cancer patient management. Mol. Cancer Res. 8(9), 1175-1187 (2010
5. Tuna M, Amos CI. Genomic sequencing in cancer. Cancer Lett. 12, S0304-S3835 (2012
6. Beck CR, Collier P, Macfarlane C et al. LINE-1 retrotransposition activity in human genomes. Cell 141(7), 1159-1170 (2010
7. Huang CR, Schneider AM, Lu Y et al. Mobile interspersed repeats are major structural variants in the human genome. Cell 141(7), 1171-1182 (2010
8. Murphy SJ, Cheville JC, Zarei S et al. Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res. 19(5), 395-406 (2012
9. O'Daniel JM, Lee K. Whole-genome and whole-exome sequencing in hereditary cancer: Impact on genetic testing and counseling. Cancer J. 18(4), 287-292 (2012
10. Tran B, Dancey JE, Kamel-Reid S et al. Cancer genomics: Technology, discovery, and translation. J. Clin. Oncol. 30(6), 647-660 (2012
11. Erlich Y, Edvardson S, Hodges et al. Exome sequencing and disease-network analysis of a single family implicate a mutation in KIF1A in hereditary spastic paraparesis. Genome Res. 21(5), 658-664 (2011
12. Teer JK, Mullikin JC. Exome sequencing: The sweet spot before whole genomes. Hum. Mol. Genet. 19(R2), R145-R151 (2010
13. Gilissen C, Hoischen A, Brunner HG, Veltman JA. Unlocking Mendelian disease using exome sequencing. Genome Biol. 12(9), 228 (2011
14. Sirmaci A, Edwards YJ, Akay H, Tekin M. Challenges in whole exome sequencing: An example from hereditary deafness. PLoS One 7(2), e32000 (2012
15. Singleton AB. Exome sequencing: A transformative technology. Lancet Neurol. 10(10), 942-946 (2011
16. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 18(9), 1509-1517 (2008
17. Morrissy AS, Morin RD, Delaney A et al. Next-generation tag sequencing for cancer gene expression profiling. Genome Res. 19(10), 1825-1835 (2009
18. Wang Z, Gerstein M, Snyder M. RNA-seq: A revolutionary tool for transcriptomics. Nat. Rev. Genet. 10(1), 57-63 (2009
19. Campbell PJ, Stephens PJ, Pleasance ED et al. Identification of somatically acquired rearrangements in cancer using genome wide massively parallel paired-end sequencing. Nat. Genet. 40(6), 722-729 (2008
20. Wu K, House L, Liu W, Cho WC. Personalized targeted therapy for lung cancer. Int. J. Mol. Sci. 13(9), 11471-11496 (2012
21. Li H, Pan Y, Li Y et al. Frequency of well identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 79(1), 8-13 (2013
22. Couraud S, Zalcman G, Milleron B et al. Lung cancer in never smokers -a review. Eur. J. Cancer 48, 1299-1311 (2012
23. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339-346 (2005
24. Ren S, Kuang P, Zheng L et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem. Biophys. 64(2), 155-160 (2012
25. Cheng L, Alexander RE, Maclennan GT et al. Molecular pathology of lung cancer: Key to personalized medicine. Mod. Pathol. 25(3), 347-369 (2012
26. Zhang Y, Sun Y, Pan Y et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin. Cancer Res. 18(7), 1947-1953 (2012
27. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29(15), 2121-2127 (2011
28. Marchetti A, Del Grammastro M, Filice G et al. Complex mutations and subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: Potential clinical implications. PLoS One 7(7), e42164 (2012
29. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005
30. Su KY, Chen HY, Li KC et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30(4), 433-440 (2012
31. Jung Y, Kim P, Jung Y et al. Discovery of ALK-PTPN3 gene fusion from human non small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 51(6), 590-597 (2012
32. Kalari KR, Rossell D, Necela BM et al. Deep sequence analysis of non-small cell lung cancer: Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations. Front. Oncol. 2, 12 (2012
33. Ju YS, Lee WC, Shin JY et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22(3), 436-445 (2012
34. Kohno T, Ichikawa H, Totoki Y et al. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 18(3), 375-377 (2012
35. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18(3), 382-384 (2012
36. Imielinski M, Berger AH, Hammerman PS et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150(6), 1107-1120 (2012
37. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069-1075 (2008
38. Greulich H, Kaplan B, Mertins P et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl Acad. Sci. USA 109(36), 14476-14481 (2012
39. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417), 519-525 (2012
40. Daniels M, Goh F, Wright CM et al. Whole genome sequencing for lung cancer. J. Thorac. Dis. 4(2), 155-163 (2012
41. Govindan R, Hammerman SP, Hayes ND et al. Comprehensive genomic characterization of squamous cell carcinoma of the lung. J. Clin. Oncol. 30, Abstract 7006 (2012
42. Li Y, Zhang L, Ball RL et al. Comparative analysis of somatic copy number alterations across different human cancer types reveals two distinct classes of breakpoint hotspots. Hum. Mol. Genet. 21(22), 4957-4965 (2012
43. Lin K, Taylor JR Jr, Wu TD et al. TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS One 6(4), e18608 (2011
44. Yao C, Li H, Shen X, He Z, He L, Guo Z. Reproducibility and concordance of differential DNA methylation and gene expression in cancer. PLoS One 7(1), e29686 (2012
45. Liu P, Morrison C, Wang L et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 33(7), 1270-1276 (2012
46. Zhuang J, Jones A, Lee SH et al. The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet. 8(2), e1002517 (2012
47. Pleasance ED, Stephens PJ, O'Meara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278), 184-190 (2010
48. Keller A, Backes C, Leidinger P et al. Next generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Mol. Biosyst. 7(12), 3187-3199 (2011
49. Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465(7297), 473-477 (2010
50. Carvalho RH, Haberle V, Hou J et al. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin. 5(1), 9 (2012
51. Beane J, Vick J, Schembri F et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev. Res. 4(6), 803-817 (2011